Quick Answer
Dare Bioscience, Inc. reported Total Revenue of $1.03 million for fiscal year 2025.
Dare Bioscience, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.03M +10429.4% |
$9.8K -99.7% |
$2.81M -71.9% |
$10.00M | $0.00 | — |
| Revenue (ASC 606) | $1.03M +10429.4% |
$9.8K -99.7% |
$2.81M -71.9% |
$10.00M | $0.00 | — |
| Net Income | -$13.40M -230.6% |
-$4.05M +86.6% |
-$30.16M +2.5% |
-$30.95M +20.0% |
-$38.70M -41.2% |
-$27.40M -92.1% |
| Diluted EPS | -$1.20 -150.0% |
-$0.48 +88.4% |
-$4.15 -1021.6% |
-$0.37 +41.3% |
-$0.63 +30.8% |
-$0.91 |
| Total Assets | $32.47M +46.9% |
$22.10M +3.8% |
$21.28M -51.4% |
$43.83M -21.5% |
$55.81M +639.1% |
$7.55M +1.5% |
| Cash and Equivalents | $24.71M +57.4% |
$15.70M +49.8% |
$10.48M -69.8% |
$34.67M -32.9% |
$51.67M +1006.6% |
$4.67M -2.3% |
| Stockholders Equity | $2.84M +147.3% |
-$6.01M -19.1% |
-$5.05M -145.4% |
$11.11M -71.3% |
$38.75M +3464.9% |
-$1.15M -361.3% |
| R&D Expense | $5.52M -61.4% |
$14.31M -33.6% |
$21.54M -28.3% |
$30.04M -1.9% |
$30.62M +47.4% |
$20.77M +143.0% |
| Operating Income | -$13.55M +42.2% |
-$23.45M +24.2% |
-$30.94M +1.4% |
-$31.39M +19.7% |
-$39.07M -42.6% |
-$27.40M -91.0% |
| Shares Outstanding | 14.50M -85.7% |
101.10M +1113.5% |
8.33M -90.2% |
84.83M +1.0% |
83.94M +101.8% |
41.60M +111.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.3K | -94.6% | -91.1% |
| Revenue (ASC 606) | September 30, 2025 | $2.3K | -94.6% | -91.1% |
| Net Income | September 30, 2025 | -$3.56M | +24.2% | +11.3% |
| Diluted EPS | September 30, 2025 | -$0.28 | +49.1% | +37.8% |
| Total Assets | September 30, 2025 | $30.75M | +70.3% | +136.9% |
| Cash and Equivalents | September 30, 2025 | $23.08M | +105.4% | +358.3% |
| Stockholders Equity | September 30, 2025 | $2.86M | +292.5% | +122.4% |
| R&D Expense | September 30, 2025 | $1.18M | -56.2% | -17.7% |
| Operating Income | September 30, 2025 | -$3.67M | +21.6% | +4.1% |
| Shares Outstanding | September 30, 2025 | 13.93M | +63.0% | +54.3% |
- Dare Bioscience, Inc. reported Total Revenue of $1.03 million for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +10429.4% in Total Revenue compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Revenue (ASC 606) of $1.03 million for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +10429.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Net Income of -$13.40 million for fiscal year 2025.
- Dare Bioscience, Inc. showed a decrease of -230.6% in Net Income compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Diluted EPS of $1.20 per share (loss) for fiscal year 2025.
- Dare Bioscience, Inc. showed a decrease of -150.0% in Diluted EPS compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Total Assets of $32.47 million for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +46.9% in Total Assets compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Cash and Equivalents of $24.71 million for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +57.4% in Cash and Equivalents compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Stockholders Equity of $2.84 million for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +147.3% in Stockholders Equity compared to the prior fiscal year.
- Dare Bioscience, Inc. reported R&D Expense of $5.52 million for fiscal year 2025.
- Dare Bioscience, Inc. showed a decrease of -61.4% in R&D Expense compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Operating Income of -$13.55 million for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +42.2% in Operating Income compared to the prior fiscal year.
- Dare Bioscience, Inc. reported Shares Outstanding of 14.50 million shares for fiscal year 2025.
- Dare Bioscience, Inc. showed an increase of +66.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: